Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Rhea-AI Summary

Innate Pharma (IPHA) will participate in several upcoming investor conferences. The company will be represented by senior executives including CEO Hervé Brailly, EVP Sonia Quaratino, COO Yannis Morel, and President of US Operations Arvind Sood. The schedule includes:

Jefferies Global Healthcare Conference on June 5-6, 2024, in New York.

Goldman Sachs 45th Annual Global Healthcare Conference on June 10-13, 2024, in Miami.

H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024.

Stifel 2nd European Healthcare Summit on June 25-27, 2024, in Lyon.

Positive

• Upcoming participation in high-profile conferences signals active investor engagement.
• Representation by senior executives, including the CEO and President of US Operations, indicates the company's commitment to these events.
• Participation in both physical and virtual conferences diversifies the company's investor outreach.

Negative

• No new financial or clinical data disclosed in the press release.
• The announcement does not address how these conferences will impact the company's financial outlook or stock performance.
• Potential dilution of focus with multiple events in a short time frame.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé Brailly, Chief Executive Officer, Sonia Quaratino, Executive Vice President (EVP), Chief Medical Officer, Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations.

• Jefferies Global Healthcare Conference
  Event dates: June 5-6, 2024 | New York, United States

• Goldman Sachs 45th Annual Global Healthcare Conference
  Event dates: June 10-13, 2024 | Miami, United States

• H.C. Wainwright 2^nd Annual Immune Cell Engager Virtual Conference
  Event date: June 25, 2024 | Virtual

• Stifel 2^nd European Healthcare Summit Lyon
  Event dates: June 25-27, 2024 | Lyon, France

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET^® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240527633153/en/

For additional information, please contact:

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

When will Innate Pharma participate in the Jefferies Global Healthcare Conference?

Innate Pharma will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York.

Who from Innate Pharma will attend the upcoming investor conferences?

Attendees include CEO Hervé Brailly, EVP Sonia Quaratino, COO Yannis Morel, and President of US Operations Arvind Sood.

What are the dates for the Goldman Sachs 45th Annual Global Healthcare Conference?

The Goldman Sachs 45th Annual Global Healthcare Conference will be held on June 10-13, 2024, in Miami.

Which virtual conference will Innate Pharma participate in?

Innate Pharma will participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on June 25, 2024.

Where and when is the Stifel 2nd European Healthcare Summit?

The Stifel 2nd European Healthcare Summit is scheduled for June 25-27, 2024, in Lyon, France.